Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable

Aggressive glioblastoma (GBM) has no known treatment as a primary brain tumor. Since the cancer is so heterogeneous, an immunosuppressive tumor microenvironment (TME) exists, and the blood–brain barrier (BBB) prevents chemotherapeutic chemicals from reaching the central nervous system (CNS), therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Barzegar Behrooz, Amir, Talaie, Zahra, Syahir, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415007/
https://www.ncbi.nlm.nih.gov/pubmed/36015322
http://dx.doi.org/10.3390/pharmaceutics14081697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415007/
https://www.ncbi.nlm.nih.gov/pubmed/36015322
http://dx.doi.org/10.3390/pharmaceutics14081697

Ejemplares similares